-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Digital Intelligence Empowerment, Fostering Communication and Innovation | Keyuan Pharmaceutical Invited to Attend the 2024 Active Pharmaceutical Ingredient Continuous Manufacturing Technology Conference!
Publish Time:
2024-08-03
Recently, the 2024 Active Pharmaceutical Ingredient Continuous Manufacturing Technology Exchange Conference was successfully held in Dunhua City, Jilin Province. The event brought together extensive industry expertise and collaborative efforts, fostering discussions on the latest advancements, key technological trends, and future prospects of continuous manufacturing, while also paving the way for partnerships and joint growth initiatives.
Recently, the 2024 Active Pharmaceutical Ingredient Continuous Manufacturing Technology Exchange Conference was successfully held in Dunhua City, Jilin Province. The conference brought together extensive industry expertise and collaborative efforts, fostering discussions on the latest advancements, key technological trends, and future prospects of continuous manufacturing, while also exploring opportunities for partnership and joint development.
As a leading enterprise in China’s niche segment of chemical APIs, Keyuan Pharmaceutical (stock code: 301281.SZ) was invited to attend the conference, joining numerous experts and representatives from government departments, industry associations, research institutions, and companies to jointly discuss the latest advancements and future trends in continuous manufacturing technology for APIs.
In recent years, continuous manufacturing technology has emerged as a highly promising and cutting-edge innovation in the pharmaceutical sector, achieving remarkable progress over the past few years. The pharmaceutical industry is characterized by high capital investment, substantial output, significant risks, extended timelines, and its inherently technology-intensive nature. Driving technological upgrades and comprehensively advancing digital and intelligent transformation have become essential pathways for pharmaceutical companies to achieve efficient R&D, ensure safe production, maintain compliant operations, and pursue sustainable growth.
 |
 |
Digital Intelligence Factory
Keyuan Pharmaceutical's Digital & Intelligent Manufacturing Plants – Shanghe Base, Jinan Base
At this year's exchange meeting, Keyuan Pharmaceutical showcased its practical experience and strong capabilities in digital and intelligent transformation as well as continuous manufacturing technologies. Jiang Hongsheng, Chairman and President of Keyuan Pharmaceutical and also Chairman of Linuo Pharmaceutical, delivered a keynote speech titled "Digital Intelligence Empowering the Transformation and Upgrading of the Pharmaceutical Industry," sharing Keyuan Pharmaceutical's initiatives and achievements in advancing digital and intelligent transformation and fostering new-quality productivity.
As a high-tech, next-generation chemical enterprise, Keyuan Pharmaceutical places great emphasis on digital and intelligent transformation and upgrading. With smart factories, digitalized workshops, and unmanned production lines as its strategic directions, the company has successfully integrated and applied enterprise resource planning, product lifecycle management, and supply chain management systems. Focused on lean, intelligent operations, Keyuan is continuously enhancing its capabilities for seamless, continuous production through technological innovation and operational optimization—effectively putting the concept of digital and intelligent transformation into practice.
Leveraging its remarkable achievements in digital and intelligent upgrades, as well as its outstanding innovation capabilities, Keyuan Pharmaceutical has proudly been listed on the Shandong Provincial Department of Industry and Information Technology's "2024 Shandong Province Benchmark Enterprises for Intelligent Transformation in the Chemical Industry." This recognition not only underscores Keyuan Pharmaceutical's accomplishments in the field of digital and intelligent manufacturing but also highlights the company's unwavering commitment to pursuing high-quality, green, and low-carbon development.
In the future, Keyuan Pharmaceutical will continue to drive digital and intelligent transformation and upgrading, further advancing continuous manufacturing technologies to set new benchmarks for high-quality development in the chemical industry, and contributing even more wisdom and strength to the advancement of China’s pharmaceutical sector.
Latest News
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline